FIELD: medicine.
SUBSTANCE: invention relates to 4-(3-((2-adamantyl)amino)-3-oxoprop-1-en-1-yl)-N-hydroxybenzamide of formula I as a neuroprotective compound, including an agent for the treatment of Alzheimer's disease.
EFFECT: Alzheimer's disease treatment drug.
1 cl, 3 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
TARGETED NON-INVASIVE TRANSPLANTATION INTO BRAIN OF FUNCTIONALLY ACTIVE MITOCHONDRIA FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2744453C2 |
HYDROCORTISONE DERIVATIVE FOR ALZHEIMER'S DISEASE TREATMENT | 2019 |
|
RU2748437C2 |
APPLICATION OF PROTEIN YB-1 AND ITS FRAGMENTS FOR PRODUCTION OF MEDICATIONS IN TREATMENT OF ALZHEIMER'S DISEASE | 2013 |
|
RU2561050C2 |
USE OF A BENZOPYRAN DERIVATIVE FOR THE TREATMENT OF DEMENTIA OF ALZHEIMER'S TYPE ASSOCIATED WITH CALCIUM DYSREGULATION | 2023 |
|
RU2804398C1 |
ANIMAL MODEL OF ZINC-DEPENDENT AMYLOIDOGENESIS IN ALZHEIMER'S DISEASE | 2021 |
|
RU2781331C1 |
PEPTIDE HAVING NEUROPROTECTIVE AND NOOTROPIC ACTIVITY AND PHARMACEUTICAL COMPOSITION BASED THEREON | 2014 |
|
RU2557003C2 |
PEPTIDE HAVING THERAPEUTIC EFFECT AGAINST ALZHEIMER'S DISEASE | 2018 |
|
RU2677296C2 |
METHOD OF DETECTING AMYLOID PEPTIDE MODIFICATIONS USING HIGH-SPECIFIC ANTIBODIES | 2019 |
|
RU2708465C1 |
PEPTIDE HAVING CURATIVE EFFECT AGAINST ALZHEIMER DISEASE | 2014 |
|
RU2558242C1 |
HYDROXAMIC ACIDS, 4-AMINOQUINAZOLINE DERIVATIVES WITH ANTITUMOR ACTIVITY | 2022 |
|
RU2802463C1 |
Authors
Dates
2022-11-23—Published
2022-03-22—Filed